Patents by Inventor Felix Deanda, Jr.

Felix Deanda, Jr. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BICYCLIC PYRAZOLE BRUTON'S TYROSINE KINASE INHIBITORS
    Publication number: 20220213092
    Abstract: The present invention provides for compounds of formula (I) wherein A, R1, R2, R4, W, m, and n have any of the values defined herein, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of CLL and/or SLL.
    Type: Application
    Filed: December 16, 2021
    Publication date: July 7, 2022
    Inventors: David A. DeGoey, Felix DeAnda, Jr., Amanda W. Dombrowski, Igor Dubovyk, Stephen N. Greszler, Dimitri Khrakovsky, Chih-Hung Lee, James N. Newton, Elizabeth L. Noey, Akinori Okano, Kevin B. Sippy, Andrew J. Souers, Longcheng Wang, Noel S. Wilson, Jeffery A. Zablocki
  • PYRAZOLO[3,4-b]PYRIDINE AND PYRROLO[2,3-b]PYRIDINE INHIBITORS OF BRUTON'S TYROSINE KINASE
    Publication number: 20180194762
    Abstract: Disclosed are pyrazolo[3,4-b]pyridine and pyrrolo[2,3-b]pyridine inhibitors of Bruton's tyrosine kinase (Btk). Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are described, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Application
    Filed: January 8, 2018
    Publication date: July 12, 2018
    Inventors: Gordana B. Atallah, Wei Chen, Dimitry Khrakovsky, Longcheng Wang, Zhaozhong Jon Jia, Felix DeAnda, JR.
  • 2-[2-{phenylamino}-1H-pyrrolo[2,3-D]pyrimidin-4-yl)amino] benzamide derivatives as IGF-1R inhibitors for the treatment of cancer
    Patent number: 7981903
    Abstract: Novel pyrrolopyrimidines as shown in formula (I): and pharmaceutically acceptable derivatives thereof. The compounds are useful in the inhibition of IGF-1R.
    Type: Grant
    Filed: August 6, 2008
    Date of Patent: July 19, 2011
    Assignee: GlaxoSmithKline LLC
    Inventors: Stanley Dawes Chamberlain, Felix Deanda, Jr., Roseanne Gerding, Masaichi Hasegawa, Kevin Kuntz, Huangshu Lei, Yasushi Miyazaki, Naohiko Nishigaki, Samarjit Patnaik, Aniko Redman, John Brad Shotwell, Kirk Stevens, Joseph Wilson, Bin Yang
  • 2-[2--1H-Pyrrolo[2,3-D]Pyrimidin-4-YL)Amino] Benzamide Derivatives As IGF-1R Inhibitors For The Treatment Of Cancer
    Publication number: 20100204196
    Abstract: Novel pyrrolopyrimidines as shown in formula (I): and pharmaceutically acceptable derivatives thereof. The compounds are useful in the inhibition of IGF-1R.
    Type: Application
    Filed: August 6, 2008
    Publication date: August 12, 2010
    Inventors: Stanley Dawes Chamberlain, Felix Deanda, JR., Roseanne Gerding, Masaichi Hasegawa, Kevin Kuntz, Huangshu Lei, Yasushi Miyazaki, Naohiko Nishigaki, Samarjit Patnaik, Aniko Redman, John Brad Shotwell, Kirk Stevens, Joseph Wilson, Bin Yang
  • Chemical Compounds
    Publication number: 20100113445
    Abstract: The present invention relates to dianilinopyrimidine derivatives, compositions and medicaments containing the same, as well as processes for the preparation and use of such compounds, compositions and medicaments. Such dianilinopyrimidine derivatives are useful in the treatment of diseases associated with inappropriate Wee1 kinase activity.
    Type: Application
    Filed: March 12, 2008
    Publication date: May 6, 2010
    Inventors: Felix Deanda, JR., David Harold Drewry, Paul Reid
  • Chemical Compounds
    Publication number: 20100105674
    Abstract: The present invention relates to dianilinopyrimidine derivatives, compositions and medicaments containing the same, as well as processes for the preparation and use of such compounds, compositions and medicaments. Such dianilinopyrimidine derivatives are useful in the treatment of diseases associated with inappropriate Wee1 kinase activity.
    Type: Application
    Filed: March 12, 2008
    Publication date: April 29, 2010
    Inventors: Felix Deanda Jr., David Harold Drewry, James Andrew Linn, Paul Reid
  • CCR5 antagonists as therapeutic agents
    Patent number: 7645771
    Abstract: The present invention relates to compounds of formula (I) or a pharmaceutically acceptable derivatives thereof, useful in the treatment of prophylazis of CCR5-related diseases and disorders, for example, in the inhibition of HIV replication, the prevention or treatment of HIV infection, and in the treatment of the resulting acquired immune deficiency syndrome (AIDS).
    Type: Grant
    Filed: December 12, 2003
    Date of Patent: January 12, 2010
    Assignee: SmithKline Beecham Corp.
    Inventors: Wieslaw Mieczyslaw Kazmierski, Chrisopher Joseph Aquino, Neil Bifulco, Eric Eugene Boros, Brian Andrew Chauder, Pek Yoke Chong, Maosheng Duan, Felix Deanda, Jr., Cecilia Suarez Koble, Ed Williams McLean, Jennifer Poole Peckham, Angilique C Perkins, James Benjamin Thompson, Dana Vanderwall